Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: A randomized clinical trial

JAMA

Volumn 309, Issue 12, 2013, Pages 1268-1277

  Redfield, Margaret M ^a   Chen, Horng H ^a   Borlaug, Barry A ^a   Semigran, Marc J ^b   Lee, Kerry L ^c   Lewis, Gregory ^b   LeWinter, Martin M ^e   Rouleau, Jean L ^g   Bull, David A ^h   Mann, Douglas L ⁱ   Deswal, Anita ^j   Stevenson, Lynne W ^k   Givertz Elizabeth O Ofili, Michael M ^k,l   O'Connor, Christopher M ^m   Felker, G Michael ^m   Goldsmith, Steven R ⁿ   Bart, Bradley A ⁿ   McNulty, Steven E ^d   Ibarra, Jenny C ^d   Lin, Grace ^a   Oh, Jae K ^a   Patel, Manesh R ^m   Kim, Raymond J ^c,m   Tracy, Russell P ^f   Velazquez, Eric J ^d   Anstrom, Kevin J ^c   Hernandez, Adrian F ^d   Mascette, Alice M ^o   Braunwald, Eugene ^k   more..

^a MAYO CLINIC   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF VERMONT   (United States)

^g MONTREAL HEART INSTITUTE   (Canada)

^h UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

ⁱ BARNES JEWISH HOSPITAL   (United States)

^j BAYLOR COLLEGE OF MEDICINE   (United States)

^k BRIGHAM AND WOMEN S HOSPITAL   (United States)

^l MOREHOUSE SCHOOL OF MEDICINE   (United States)

^m DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁿ HENNEPIN COUNTY MEDICAL CENTER   (United States)

^o NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP; PLACEBO; SILDENAFIL; UNCLASSIFIED DRUG; PHOSPHODIESTERASE V INHIBITOR; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONE;

ADULT; AGED; ARTICLE; CARDIOPULMONARY EXERCISE TEST; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MAGNETIC RESONANCE; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DOPPLER ECHOCARDIOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; ENZYME INHIBITION; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; FLUSHING; FOLLOW UP; HEALTH STATUS; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE FILLING PRESSURE; HUMAN; HYPOTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MULTICENTER STUDY; NORTH AMERICA; OUTCOME ASSESSMENT; OUTPATIENT; OXYGEN CONSUMPTION; PARALLEL DESIGN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY ARTERY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; BLOOD PRESSURE; CONTROLLED CLINICAL TRIAL; HEART STROKE VOLUME; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT OUTCOME; WALKING;

AGED; BLOOD PRESSURE; DOUBLE-BLIND METHOD; EXERCISE TOLERANCE; FEMALE; HEALTH STATUS; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; OXYGEN CONSUMPTION; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; STROKE VOLUME; SULFONES; TREATMENT OUTCOME; WALKING;

MLCS; MLOWN;

EID: 84875531214     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.2024     Document Type: Article

References (31)

1. Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis. 2005;47(5):320-332. (Pubitemid 40884561)
2. Shah RV, Desai AS, Givertz MM. The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis. J Card Fail. 2010;16(3):260-267.
3. Redfield MM, Borlaug BA, Lewis GD, et al Heart Failure Clinical Research Network. PhosphdiesteRasE-5 inhibition to improve clinical status and exercise capacity in diastolic heart failure (RELAX) trial: rationale and design. Circ Heart Fail. 2012;5(5):653-659.
4. Galiè N, Ghofrani HA, Torbicki A, et al Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148-2157. (Pubitemid 41653106)
5. Lewis GD, Shah R, Shahzad K, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation. 2007;116(14):1555-1562. (Pubitemid 47511419)
6. Guazzi M, Vicenzi M, Arena R. Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study. Eur J Heart Fail. 2012;14(1):82-90.
7. Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail. 2011;4(1):8-17.
8. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011;124(2):164-174.
9. Fletcher GF, Balady G, Froelicher VF, Hartley LH, Haskell WL, Pollock ML; Writing Group. Exercise standards: a statement for healthcare professionals from the American Heart Association. Circulation. 1995;91(2):580-615.
10. Packer M. Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure. J Card Fail. 2001;7(2):176-182. (Pubitemid 32554111)
11. Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med. 1998;158(5 Pt 1):1384-1387.
12. Khan MN, Pothier CE, Lauer MS. Chronotropic incompetence as a predictor of death among patients with normal electrograms takingbeta blockers (metoprolol or atenolol). Am J Cardiol. 2005;96(9):1328-1333. (Pubitemid 41505419)
13. Chirinos JA, Segers P, De Buyzere ML, et al. Left ventricular mass: allometric scaling, normative values, effect of obesity, and prognostic performance. Hypertension. 2010;56(1):91-98.
14. Feldman AM, Silver MA, Francis GS, et al PEECH Investigators. Enhanced external counterpulsation improves exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol. 2006;48(6):1198-1205. (Pubitemid 44345118)
15. Abraham WT, Fisher WG, Smith AL, et al; MIRACLE Study Group, Multicenter InSync Randomized Clinical Evaluation. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346(24):1845-1853.
16. Lang RM, Bierig M, Devereux RB, et al Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18(12):1440-1463.
17. Hundley WG, Kitzman DW, Morgan TM, et al. Cardiac cycle-dependent changes in aortic area and distensibility are reduced in older patients with isolated diastolic heart failure and correlate with exercise intolerance. J Am Coll Cardiol. 2001;38(3):796-802. (Pubitemid 32835755)
18. Shah SJ, Heitner JF, Sweitzer NK, et al. Baseline characteristics of patients in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circ Heart Fail. 2012.
19. Forfia PR, Borlaug BA. Letter by Forfia and Borlaug regarding article, "Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study." Circulation. 2012;125(8):e408-e410. doi:10.1161/CIRCULATIONAHA.111.064584.
20. Nagendran J, Archer SL, Soliman D, et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation. 2007;116(3):238-248. (Pubitemid 47196559)
21. Xie YP, Chen B, Sanders P, et al. Sildenafil prevents and reverses transverse-tubule remodeling and Ca(2+) handling dysfunction in right ventricle failure induced by pulmonary artery hypertension. Hypertension. 2012;59(2):355-362.
22. Borgdorff MA, Bartelds B, Dickinson MG, et al. Sildenafil enhances systolic adaptation, but does not prevent diastolic dysfunction, in the pressure-loaded right ventricle. Eur J Heart Fail. 2012;14(9):1067-1074.
23. Nagayama T, Hsu S, Zhang M, et al. Pressure-overload magnitude-dependence of the antihypertrophic efficacy of PDE5A inhibition. J Mol Cell Cardiol. 2009;46(4):560-567.
24. Takimoto E, Champion HC, Li M, et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005;11(2):214-222. (Pubitemid 40321358)
25. Lewis GD, Lachmann J, Camuso J, et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation. 2007;115(1):59-66. (Pubitemid 46058612)
26. Guazzi M, Tumminello G, Di Marco F, Fiorentini C, Guazzi MD. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol. 2004;44(12):2339-2348. (Pubitemid 39647608)
27. Borlaug BA, Olson TP, Lam CS, et al. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2010;56(11):845-854.
28. Bishu K, Deswal A, Chen HH, et al. Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction. Am Heart J. 2012;164(5):763-770 e763.
29. Tapia E, Sanchez-Lozada LG, Soto V, et al. Sildenafil treatment prevents glomerular hypertension and hyperfiltration in rats with renal ablation. Kidney Blood Press Res. 2012;35(4):273-280.
30. Medeiros PJ, Villarim Neto A, Lima FP, Azevedo IM, Leão LR, Medeiros AC. Effect of sildenafil in renal ischemia/reperfusion injury in rats. Acta Cir Bras. 2010;25(6):490-495.
31. Choi DE, Jeong JY, Lim BJ, et al. Pretreatment of sildenafil attenuates ischemia-reperfusion renal injury in rats. Am J Physiol Renal Physiol. 2009;297(2):F362-F370.